TALIM study, for the treatment of patients affected by persisent or recurrent Multiple Myeloma with the drug teclistamab and infusions of lymphocytes from the same patient.

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Fondazione Gimema Franco Mandelli Onlus

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Hemic and Lymphatic Diseases [C15]

Decision date (initial)

2026-04-14

Transition trial

No

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

No

Funding sources

Fondazione GIMEMA Franco Mandelli onlus · Janssen-Cilag S.p.A

External identifiers

EU CT number

2025-521827-61-00

ClinicalTrials.gov

NCT06880601

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Efficacy

To evaluate the efficacy of the combination of Te and ALI in terms of Duration of Response (DOR)

Secondary objectives 5

1. Response according to the IMWG criteria (15)
2. Progression Free Survival
3. Overall Survival
4. Safety profile
5. Biologic ancillary studies

Conditions and MedDRA coding

refractory/relapsed multiple myeloma

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 14

1. Patient has a confirmed diagnosis of MM according to the WHO 2022 classification (18)
2. Patient age is ≥ 18 years of age
3. Patient has a relapsed or refractory disease as defined below: 1.Relapsed disease is defined as an initial response to previous treatment, followed by confirmed progressive disease by the International Myeloma Working Group (IMWG) (15) criteria >60 days after cessation of treatment 2. refractory disease is defined as failure to achieve a response or confirmed progressive disease by IMWG criteria (15) during previous treatment or ≤60 days after cessation of treatment
4. Previous treatment with 1 or 2 lines of treatment (induction plus autologous stem cell transplant plus consolidation and maintenance has to be considered one single line)
5. Previous triple exposure that included an IMID, a PI, and an anti-CD38 antibody (patients with no response or relapse after front line therapy with Dara-VTD or Dara-VRD are eligible)
6. Progressive active symptomatic disease
7. Patient has measurable disease as defined by any of the following: Serum M-protein level ≥0.5 g/dL; or Urine M-protein level ≥200 mg/24 hours; or Serum immunoglobulin free light chain ≥10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
9. Able to adhere to the study visit schedule and all the other protocol procedures and requirements
10. Patient has the following laboratory parameters: 1.Total lymphocytes count ≥ 0.3 x 109 /L 2.Platelet count > 50 x 109 /L unless due to bone marrow involvement by MM 3.Conjugated bilirubin up to 2 x ULN unless due to liver involvement by MM 4. Alkaline phosphatase and transaminases up to 2 x ULN unless due to liver involvement by MM 5.Creatinine clearance ≥ 30 ml/min
11. A female participant of childbearing potential must have a negative highly sensitive serum pregnancy test within 2-7 days prior to C1D1
12. Life expectancy ≥ 2 months
13. Successful collection of at least 100 x 106 /kg autologous lymphocytes before starting treatment with Te.
14. Patient understands and voluntarily signs an informed consent form.

Exclusion criteria 18

1. Previous treatment with > 2 lines of therapy
2. Patient has active central nervous system involvement with MM
3. Received any prior BCMA-directed therapy
4. Received the following prior antimyeloma therapy, within the specified time frame prior to enrollment: 1.Targeted therapy, epigenetic therapy, or treatment with an investigational drug or an invasive investigational medical device within 21 days or ≥5 half-lives, whichever is less 2.Investigational vaccine within 4 weeks 3.Monoclonal antibody therapy wihin 21 days 4.Cytotoxic therapy within 21 days 5.PI therapy within 14 days 6.IMiD agent therapy within 14 days 7.Radiotherapy within 14 days or focal radiation within 7 days.
5. Gene-modified adoptive cell therapy (eg, chimeric antigen receptor modified T cells, NK cells) within 3 months
6. Stem cell transplant: 1.previous allogeneic stem cell transplant 2.autologous stem cell transplant performed within 12 weeks
7. Patients with plasma cell leukemia (presence of 5% or more plasma cells in conventional peripheral blood smear white blood cell differential count)
8. Contraindications or life-threatening allergies, hypersensitivity, or intolerance to any study drug or its excipients
9. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM)
10. Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
11. Any active malignancy (ie, progressing/requiring treatment change in the last 24 months) other than MM. The only allowed exceptions are malignancies treated within the last 24 months that are considered cured: 1.Non-muscle invasive bladder cancer (solitary Ta-PUNLMP or low grade, <3 cm, no CIS) 2.Non-melanoma skin cancers treated with curative therapy or localized melanoma treated with curative surgical resection 3.Non-invasive cervical cancer 4.Breast cancer: treated lobular carcinoma in situ or ductal carcinoma in situ, or history of localized breast cancer (anti-hormonal therapy is permitted) 5.Localized prostate cancer (M0, N0) with a Gleason Score ≤7a, treated locally(RP/RT/focal treatment) 6.Other malignancy considered cured with minimal risk of recurrence in consultation with physician.
12. Clinically relevant and active liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
13. Patient has any other concurrent severe and/or uncontrolled medical condition(s) (e.g., uncontrolled diabetes mellitus, uncontrolled hypertension, active/symptomatic coronary artery disease, chronic obstructive pulmonary disease (COPD), active hemorrhage, psychiatric illness, active or uncontrolled infection that in the investigator opinion places the patient at unacceptable risk and would prevent the subject from signing the informed consent form
14. Participant had major surgery or had significant traumatic injury within 2 weeks prior to enrollment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study
15. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment
16. Patient has a known history of HIV seropositivity
17. Seropositive for hepatitis B: defined by a positive test for HbsAg. Participants with resolved infection (ie, participants who are HbsAg negative with antibodies to total anti-HBc with or without the presence of anti-HBs) must be screened using RT-PCR measurement of HBV DNA levels. Participants with a known history of HBV infection must be screened using RT-PCR measurement of HBV DNA levels irrespective of serological results. Those who are RT-PCR positive will be excluded. Participants with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by RT-PCR (see Appendix 12)
18. Active hepatitis C infection as measured by positive HCV-RNA testing. Participants with a history of HCV antibody positivity must undergo HCV-RNA testing. If a participant with history of chronic hepatitis C infection (defined as both HCV antibody and HCV-RNA positive) completed antiviral therapy and has undetectable HCV-RNA 12 weeks following the completion of therapy, the participant is eligible for the study.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. Estimation of the DoR at 18 months from the combination therapy (24 months from the beginning of Te monotherapy).

Secondary endpoints 4

1. Response at cycles 5 and every 3 cycles according to the IMWG criteria (15)
2. PFS at 18 months from beginning of therapy with Te and ALI
3. Overall Survival at 24 months from the beginning of therapy with Te
4. Safety profile overall and with a focus on CRS according to ASTCT (16) and ICANS according to ASTCT (16)

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Fondazione Gimema Franco Mandelli Onlus

Sponsor organisation

Fondazione Gimema Franco Mandelli Onlus

Address

Via Casilina 5

City

Rome

Postcode

00182

Country

Italy

Scientific contact point

Organisation

Fondazione Gimema Franco Mandelli Onlus

Contact name

Data Center

Public contact point

Organisation

Fondazione Gimema Franco Mandelli Onlus

Contact name

Data Center

Third parties 3

Locations

1 EU/EEA country · 21 investigational sites

By country

Investigational sites

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Documents 9 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications